Financials
This section of the Anika Therapeutics, Inc. InvestorRoom houses up to date financial reporting information and interactive tools to provide you with the resources you need to manipulate and understand our current financial standing.
Please note: All data in this section is provided by a 3rd party provider and may be delayed up to 20 minutes. Anika Therapeutics assumes no responsibility for the accuracy of this data and provides it for informational purposes only.
NASDAQANIK
| Beta | 0.86 |
|---|---|
| Shares Outstanding | 14.6M |
| Average Volume (10 days) | 148.2K |
| Qtrly Dividend (Ann. Yield) | -- (--) |
Analyst Views
| Current Mean Recommendation | Strong Buy |
|---|
| Strong Buy | 1 | |
|---|---|---|
| Buy | 0 | |
| Hold | 0 | |
| Underperform | 0 | |
| Sell | 0 |
Recent Insider Transactions
Anne Nunes SVP, Chief Operations Officer | (732) Dispose Oct 1, 2024 |
|---|---|
Richard Stephen Director | 5,771 Acquire Jul 9, 2024 |
Larsen Glenn Director | 5,771 Acquire Jul 9, 2024 |
Jellison William | 5,771 Acquire Jul 9, 2024 |
Capper Joseph H. | 5,771 Acquire Jul 9, 2024 |